Skip to content

Pasadena Star News

64°F
Friday, May 1st 2026

e-Edition

Trending:

Recent Quotes
My Watchlist
Indicators
Local Stocks
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Rhythm Pharmaceuticals, Inc. - Common Stock (NQ:RYTM)

105.81 -3.88 (-3.54%)
Streaming Delayed Price Updated: 2:40 PM EDT, Jul 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Rhythm Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
Rhythm Pharmaceuticals Announces The New England Journal of Medicine Publication of Phase 3 TRANSCEND Trial Results in Acquired Hypothalamic Obesity
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Announces Multiple New Data Presentations from MC4R Agonists in Acquired Hypothalamic Obesity (HO), Bardet-Biedl Syndrome (BBS) and Prader-Willi Syndrome (PWS) at ENDO 2026
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi Syndrome
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) Surpasses Q1 Estimates as U.S. Hypothalamic Obesity Launch Accelerates ↗
Via Chartmill
News headline image
Rhythm Pharmaceuticals Announces Seven Abstracts Accepted for Presentation at ENDO 2026
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Announces Publication of New Bardet-Biedl Syndrome Diagnostic Algorithm in the American Journal of Medical Genetics
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Announces New Data Presentations at the 2026 European Congress of Endocrinology
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
My Top 3 Stocks to Buy in May ↗
Forget "sell in May and go away." These stocks are good picks to buy and hold. 
Via The Motley Fool
Topics Earnings
News headline image
Rhythm Pharmaceuticals Analysts Boost Their Forecasts Following Upbeat Q1 Results ↗
Rhythm Pharmaceuticals (NASDAQ: RYTM) reported better-than-expected earnings, with strong demand for IMCIVREE and potential launches in Europe and Japan. 
Via Benzinga
News headline image
Rhythm (RYTM) Q1 2026 Earnings Call Transcript ↗
Rhythm (RYTM) Q1 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Rhythm Pharmaceuticals Announces Participation in Upcoming Bank of America Global Healthcare Conference
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Why Rhythm Pharmaceuticals Stock Triumphed on Tuesday ↗
It released an encouraging quarterly earnings report and business update before market open. 
Via The Motley Fool
News headline image
Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Announces New Data Presentations in Acquired Hypothalamic Obesity at Pediatric Endocrine Society
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Announces IMCIVREE® (Setmelanotide) Granted Marketing Authorization by European Commission for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals to Report First Quarter 2026 Financial Results on Tuesday, May 5, 2026
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Neurocrine Biosciences to Acquire Celeno Therapeutics in Rare Disease Deal
In a move that signals a significant consolidation within the rare endocrine disease market, Neurocrine Biosciences (NASDAQ: NBIX) announced on April 6, 2026, that it has entered into a definitive... 
Via MarketMinute
News headline image
Soleno Therapeutics: A Masterclass in Rare Disease Redemption and the $2.9B Exit
The following feature explores the trajectory of Soleno Therapeutics as of April 7, 2026. Introduction On the morning of April 7, 2026, the biotechnology sector is processing one of the most... 
Via Finterra
Topics Economy Intellectual Property
News headline image
Neurocrine Biosciences to Acquire Soleno Therapeutics in $2.9 Billion Deal as VYKAT™ XR Sales Soar
Shares of Soleno Therapeutics (NASDAQ: SLNO) surged more than 32% in early trading on Monday, April 6, 2026, following the blockbuster announcement that Neurocrine Biosciences (NASDAQ: NBIX) has... 
Via MarketMinute
Topics Intellectual Property
News headline image
Rhythm Pharmaceuticals Announces Changes to Board of Directors
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Is This Weight Loss Drug Stock a Buy After a New Approval? ↗
This little-known biotech company has a different strategy than the established weight-loss drug market leaders. But is it likely to be successful? 
Via The Motley Fool
News headline image
Rhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Announces Topline Results from Phase 3 EMANATE Trial
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Investment Manager Fully Exits Immunome Stock in $37.3 Million Sale, According to Latest SEC Filing ↗
Immunome develops antibody therapeutics for cancer and infectious diseases, reporting a market cap above $2 billion in the latest filing. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Investment Manager Sells $5.1 Million Worth of LQDA Stock, According to Recent SEC Filing ↗
Liquidia develops inhaled and injectable therapies for pulmonary arterial hypertension, targeting unmet needs in the U.S. biopharma market. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Rhythm Pharmaceuticals Announces Additional Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic Obesity
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharma (RYTM) Earnings Call Transcript ↗
Rhythm Pharma (RYTM) Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.